The first generic versions of Truvada (emtricitabine, tenofovir disoproxil fumarate) and Atripla (efavirenz, emtricitabine, tenofovir disoproxil fumarate) have been made available by Teva Pharmaceuticals.
Emtricitabine and Tenofovir Disoproxil Fumarate tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 17kg. The treatment is also approved for at-risk adults and adolescents weighing at least 35kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. The tablets contain 200mg of emtricitabine and 300mg of tenofovir DF (equivalent to 245mg of tenofovir disoproxil); the Wholesale Acquisition Cost (WAC) is $48.51 per tablet.
Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate tablets are indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40kg. The tablets contain 600mg of efavirenz, 200mg of emtricitabine, and 300mg of tenofovir DF; the WAC is $78.86 per tablet.
Additional information on these generic HIV treatment options can be found at tevahivgenerics.com.
Teva launches first generic versions of HIV-1 treatments Truvada® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) and Atripla® (efavirenz 600mg/emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) tablets in the US. https://www.businesswire.com/news/home/20201002005067/en/Teva-Launches-First-Generic-Versions-of-HIV-1-Treatments-TRUVADA%C2%AE-emtricitabine-200-mgtenofovir-disoproxil-fumarate-300-mg-and-ATRIPLA%C2%AE-efavirenz-600-mgemtricitabine-200-mgtenofovir-disoproxil-fumarate-300-mg-Tablets-in-the-U.S. Accessed October 5, 2020.